



Royal Brisbane and Women's Hospital

RBWH Research Report 2025

Herston Infectious Diseases Institute

**Metro North
Health**



**Queensland
Government**



Metro North Health acknowledges the Traditional Custodians of the Land upon which we live, work and walk, and pay our respects to Elders both past and present.

Published by the State of Queensland (Metro North Hospital and Health Service), June 2026



This document is licensed under a Creative Commons Attribution 3.0 Australia licence.

To view a copy of this licence, visit creativecommons.org/licenses/by/3.0/au

© State of Queensland (Metro North Hospital and Health Service) 2026

You are free to copy, communicate and adapt the work, as long as you attribute the State of Queensland (Metro North Hospital and Health Service).

For more information, contact:

RBWH Research Services, Metro North Hospital and Health Service, Level 8, Block 7, Herston QLD 4029, email RBWH_Research_ESO@health.qld.gov.au

An electronic version of this document is available at <https://metronorth.health.qld.gov.au/rbwh/research>

Disclaimer:

The content presented in this publication is distributed by the Queensland Government as an information source only. The State of Queensland makes no statements, representations or warranties about the accuracy, completeness or reliability of any information contained in this publication. The State of Queensland disclaims all responsibility and all liability (including without limitation for liability in negligence) for all expenses, losses, damages and costs you might incur as a result of the information being inaccurate or incomplete in any way, and for any reason reliance was placed on such information.

Contents

Herston Infectious Diseases Institute 4

Herston Infectious Diseases Institute

Research highlights

The Herston Infectious Diseases Institute (HeIDI) is committed to delivering innovative infectious diseases research that supports clinical excellence in the surveillance, diagnosis, and management of serious infections that impact our community. The Institute also plays a critical role supporting research in the prevention and monitoring of healthcare associated infections and in fostering strong partnerships across industry, government, and academic sectors.

In 2025, HeIDI continued to build on its established research excellence, with active research grants totalling \$57.4 million and 137 papers published in peer reviewed journals. Researchers held multiple editorial positions across leading journals, and collaborations with The University of Queensland, Queensland University of Technology, Griffith University, and CSIRO continued to flourish. This performance was underpinned by significant success in competitive funding schemes, including four current (Jason Roberts, Claire Rickard, Patrick Harris, and Bridget Barber) and one future (Jessica Schults) NHMRC Investigator Grant holders, and three current Queensland Health Clinical Research Fellowship holders (Karen Davies, Krispin Hajkowicz, and Midori Nakagaki).

Strategic partnerships remained a core strength of the Institute. A major milestone in 2025 was the establishment of the Device Related Infection Management (DRIM) Portfolio, developed in partnership with the Jamieson Trauma Institute, Queensland University of Technology, and Metro North, and led by Professor Andrej Trampuz. DRIM aims to improve outcomes for patients with device related infections through specialised clinical services, targeted education, and collaborative pre clinical and translational research.

Collaboration with CSIRO also continued to expand, most notably through the development of a Digital Twin to address antimicrobial resistance within an antimicrobial stewardship framework. Led through Redcliffe Hospital, this project is supported by a robust implementation science framework that underpins the digitally-focused methodology of the project.

Education remained central to HeIDI's mission in 2025. The HeIDI Annual Forum, held on Tuesday 25 November, attracted over 170 attendees across in person and virtual formats. The program featured sessions on environmental surveillance, novel and emerging therapeutics, clinical trials, infection prevention, and the contribution of Australian research to international sepsis guidelines.

The Forum was followed by the Lipman Oration, delivered by Professor Sandra Peake, Immediate Past Chair of the ANZICS Clinical Trials Group, Professor in the University of Adelaide's School of Medicine, and Senior Specialist in Intensive Care Medicine at The Queen Elizabeth Hospital. Professor Peake shared a compelling narrative of her career in clinical research and leadership, highlighting themes of mentorship, teamwork, diversity, passion, and professional balance.

These events concluded with a seminar on Wednesday 26 November focused on the prevention of hospital acquired airborne infections. Nearly 180 participants attended in person and virtually, hearing from local, national, and international clinical and engineering experts addressing emerging strategies for the prevention of airborne transmission in healthcare settings.

Looking ahead to 2026, HeIDI will continue to support and expand infectious diseases research and education through strong partnerships across Metro North Health and beyond.

Successful Research Higher Degree (e.g. MPhil or PhD) candidates in 2025

Name	Degree (e.g. Mphil or PhD)	Title	Month Completed	Affiliated University	Summary
Dr Tricia Kleidon	PhD	Techniques and technologies to improve first-time peripheral intravenous catheter insertion success and minimise complications	October 2025	The University of Queensland	The overarching aim of this PhD was to investigate techniques and technologies to improve PIVC first-time insertion success. There were three objectives guiding this research: 1. Describe the techniques and technologies that have been used to improve PIVC insertion success. 2. Determine associations between: a. Patient and device factors and PIVC insertion success. B. Techniques and technologies and first-time insertion success. 3. Test the utility of ultrasound (technology) to improve PIVC insertion success in a randomised controlled trial (RCT).
Dr Amy Legg	PhD	Nephrotoxicity of antibiotics in patients with Staphylococcus aureus bacteremia: incidence and outcomes	August 2025	Charles Darwin University	Nephrotoxicity of combination antibiotic therapy for Staphylococcus aureus bacteraemia. Awarded PHD excellence award from CDU, 2025.
Dr Mikaela Walker	PhD	A dynamic in vitro infection model evaluation of antibiotic regimens for the treatment of carbapenem-resistant Escherichia coli infections	2025	The University of Queensland	Focus on various combination therapies involving ceftazidime-avibactam against carbapenem-resistant E. coli.
Dr Saiyuri Naicker	PhD	Suitability of Beta-lactam and Beta-lactamase inhibitor combinations for use in outpatient parenteral antimicrobial therapy	2025	The University of Queensland	Focus on the effect of Antimicrobial de-escalation on the emergence of Antimicrobial resistance in gram negative pathogens.
Dr Nilesh Kumta	PhD	Optimising Antibiotic Dosing for Treatment of Nosocomial Central Nervous System Infections in Neurocritical Care Patients	2025	The University of Queensland	Project was a binational pharmacokinetic study aiming to optimise antibiotic dosing of critically ill patients with central nervous system infections

Name	Degree (e.g. Mphil or PhD)	Title	Month Completed	Affiliated University	Summary
Dr Paul Williams	PhD	Optimising Care of Critically Ill Patients Through Improved Antibiotic Dosing	2025	The University of Queensland	Focus on guideline-based dosing, therapeutic drug monitoring and precision dosing software.
Dr Jeremy Gower	PhD	Developing new research tools to improve our understanding of Plasmodium knowlesi biology	August 2025	Queensland University of Technology	The zoonotic malaria parasite <i>Plasmodium knowlesi</i> has emerged as a major public health problem in Southeast Asia, yet key gaps remain in our understanding of its biology, epidemiology and pathogenesis. This project developed new experimental tools to advance <i>P. knowlesi</i> research and investigate inter-species interactions. A laboratory strain was adapted to new culture conditions, enabling manufacture of a <i>P. knowlesi</i> master cell bank and establishment of an induced blood-stage malaria human challenge model, with successful pilot human infection demonstrated. In parallel, <i>P. knowlesi</i> - <i>P. falciparum</i> co-culture studies showed inhibitory effects of <i>P. falciparum</i> on <i>P. knowlesi</i> growth, providing insight into mechanisms underlying zoonotic malaria emergence.
Dr Angelica Tan	PhD	Diagnostic approaches to the detection of zoonotic <i>Plasmodium knowlesi</i> infections and the role of neutrophil activation in severe malaria	May 2025	Charles Darwin University	<i>Plasmodium knowlesi</i> is the primary cause of zoonotic malaria in Southeast Asia and can cause severe, fatal disease comparable to <i>P. falciparum</i> , making rapid diagnosis a critical priority. This thesis evaluated diagnostic and immunopathological aspects of knowlesi malaria. Two multiplex real-time PCR assays were compared, demonstrating that the lower-cost QuantiFast™ assay achieved sensitivity and specificity comparable to abTES™. Ten WHO-prequalified rapid diagnostic tests were assessed, with pan-pLDH and Pv-pLDH targets showing the highest sensitivity for <i>P. knowlesi</i> . A novel haemozoin-based magneto-optical platform demonstrated high sensitivity comparable to expert microscopy. Finally, elevated neutrophil activation markers and extracellular traps were identified in clinical infections, implicating excessive neutrophil activation in severe knowlesi pathogenesis.
Dr Sarah Hickson	PhD	Pseudomonas aeruginosa Pathogenesis Mechanisms in Bacteraemia and Infective Endocarditis	December 2024	University of Queensland	<i>Pseudomonas aeruginosa</i> is an opportunistic pathogen capable of causing a wide range of infections, facilitated by extensive virulence mechanisms that enable survival, persistence, and pathogenicity across diverse environments. These infections are often associated with high mortality and pose significant therapeutic challenges due to the prevalence of multidrug resistance among clinical strains. This thesis characterises clinical <i>P. aeruginosa</i> isolates from bacteraemia and infective endocarditis to elucidate key factors contributing to pathogenesis in these infections. The overarching aim is to identify critical disease-causing mechanisms that may serve as targets for antimicrobial interventions, thereby suggesting strategies to prevent and manage <i>P. aeruginosa</i> infections

Research Awards and Achievements

Recipient	Award	Event
Jessica Schults	The University of Queensland Foundation Research Excellence Awards	UQ FREA Awards
Claire Rickard	The University of Queensland Centre for Clinical Research Clinical Trialist of the Year.	UQCCR Director's Awards
Claire Rickard	Finalist – 2025 Researcher of the Year	Metro North Research Excellence Awards
Sally Havers	The University of Queensland Centre for Clinical Research Early Career Researcher of the Year.	UQCCR Director's Awards

Research Grants

Investigator Names (RBWH staff in bold)	RBWH Departments / Research Groups	Research Project Title	Granting Body	Total Awarded (whole all years)	Length of Awards in years and years active
Bridget Barber	Infectious Diseases	Malaria volunteer infection studies for the advancement of antimalarial therapeutics	NHMRC EL2 Investigator Grant	\$1,345,834	5 years, 2023 – 2027
Chaboyer W, Gillespie B, McInnes E, Rickard C , Scuffham P, Glasziou P, Scott I, Ullman A, Thalib L, Chopra V	HeIDI, RBWH	Centre of Research Excellence in Wiser Wound Care	NHMRC Centres of Research Excellence	\$2.5M	2020 – 2026
Davies K	HeIDI, Clinical Pharmacology	Implementation of the Medication Administration Evaluation and Feedback Tool (MAEFT): Knowledge Translation	QH Clinician Research Fellowship	\$199,202	2023 – 2026
Egerton-Warburton D, Cameron P, Cullen L, Teede H, Rickard C , Morphet J, Fatovich D, O'Reilly G, Callander E, Keijzers G, Kuhn L, Enticott J, Buntine P, Tran V, Heiss L	HeIDI, RBWH	Just Say No to the Just in Case Cannula: An Implementation Science Trial with Roadmap for National Roll Out	MRFF Clinical Trials Activity Stream 5 MRF2023389	\$2,895,091	2023 – 2027
Evans I, Smith D, Burke A, Roberts JA , Hernandez-Mitre MP	HeIDI	A population pharmacokinetic study of elexacaftor, tezacaftor and ivacaftor (Trikafta) in patients with Cystic Fibrosis with the development of therapeutic drug monitoring targets	The Prince Charles Hospital Innovation Grant 2023	\$97,506	2 years, 2024 – 2025

Investigator Names (RBWH staff in bold)	RBWH Departments / Research Groups	Research Project Title	Granting Body	Total Awarded (whole all years)	Length of Awards in years and years active
Freya Fowkes, Leanne Robinson, Julie Simpson, Ric Price, Peter Gethring, Alyssa Barry, James Beeson, Kamala Thriemer, Bridget Barber , Ivo Mueller	Infectious Diseases	Malaria Elimination Centre for Research Excellence: MASTER-MAP (Modern Acceleration STRategies for ERadication of Malaria in the Asia-Pacific)	NHMRC (Centre of Research Excellence grant)	\$3,000,000	5 years, 2023 – 2027
Gibbons K, Roberts JA , Raman S, Butt W, Ullman A, Schlapbach L, Erickson S, Festa M, Irwin A, Parker S, Narayan S, Gilholm P, Blythe R.	HeIDI	Comparison of Continuous and Extended vs Intermittent Beta-Lactam Infusions in Critically Ill Children with Sepsis – the BUILD Multicentre Binational Randomised Controlled Trial	2023 Medical Research Future Fund (MRFF) Clinical Trials Activity (MRFF 2039667)	\$3,019,732	5 years, 2025 – 2030
Krispin Hajkowicz , Kym Lowry, Nicolas Smoll, Colleen Lau	HeIDI	An Observational Study of the Epidemiology, Burden of Disease and Genomics of Respiratory Syncytial Virus Infection in Adults aged 18 and Older Living in Queensland, Australia	GSK	\$683,000	4 years, 2023 – 2027
Krispin Hajkowicz , Patrick Harris , Andrea Henden , Kym Lowry	HeIDI	Rapid Clinical Genomics to Transform Diagnosis of Febrile Neutropenia in People with a Haematological Malignancy	Queensland Health Targeted Clinical Research Fellowship (Genomics)	\$124,932	2 years, 2024 – 2025
Krispin Hajkowicz , Jayesh Dhanani , Kym Lowry, Patrick Harris , Jason Roberts , Timothy Kidd, Jessica Schults	HeIDI	Right First Time - Ultra-Rapid Infection Diagnosis for Critically Ill Patients in RBWH ICU	RBWH Foundation Grant	\$46,203	2 years, 2024 – 2025
Harris PNA	HeIDI	New diagnostic strategies for antibiotic-resistant infections	NHMRC Investigator Grant EL2	\$1,362,265	4 years, 2025 – 2029
Harris PNA	HeIDI	Henderson Foundation Fellowship	The Henderson Foundation	\$350,000	5 years, 2025 – 2030

Investigator Names (RBWH staff in bold)	RBWH Departments / Research Groups	Research Project Title	Granting Body	Total Awarded (whole all years)	Length of Awards in years and years active
Harris PNA , Subedi S, Gibbons K, Shekar K, Peri AM , Tabah A, Irwin A, Isler B, Edmunds K, Raman S, Roberts JA , Forde B, Graves B , Schembri M	HeIDI, Infectious Diseases	Integrating sequencing technologies for bloodstream infection and sepsis diagnostics in critically-ill patients	MRFF 2024 Genomics Health Futures	\$2,926,024	5 years, 2025 – 2030
Lovegrove J , Havers S , Schults J , Smith S, Joyce S, Rickard, C	HeIDI	Safe PIVCs across Metro North and beyond – Foundation for a Clinical Quality Registry	2024 HeIDI Early Career Researcher Enabling Grants	\$14,489	2024 – 2025
Lovegrove J , Rickard C , Ray-Barruel G , Havers S , Williams E, Smith S	HeIDI	Barriers and facilitators to implementing standards for peripheral intravenous catheter care: A descriptive qualitative study of hospital clinicians and policymakers across Australia	Australasian College of Infection Prevention and Control Early Career Researcher Grant 2025	\$11,785	2025
Gail Matthews, Nila Dharan, Anthony Kelleher, Virginia Wiseman, Stuart Turville, Steven Tong, Bridget Barber , Gregory Dore, James McMahon, Claudia Dobler, Benjamin Rogers, Susan Maddocks, Mark Boyd, Janine Trevillyan, Owen Robinson	Infectious Diseases	Strategies and Treatments for Respiratory Infections and Viral Emergencies (STRIVE)	NHMRC (MRFF International Clinical Trial Collaborations)	\$1,993,166	4 years, 2023 – 2026
McQuilten Z, Wood E, Rickard C , Agar M, Hawkes E, Henden A , Roberts JA , Petrie D, Rutherford C, Le TTP	HeIDI, RBWH	A Centre of Research Excellence in Supportive Care for People with Blood Cancers	NMHCRC 2025 Centres of Research Excellence	\$3,000,000	5 years, 2025 – 2030

Investigator Names (RBWH staff in bold)	RBWH Departments / Research Groups	Research Project Title	Granting Body	Total Awarded (whole all years)	Length of Awards in years and years active
McQuilten Z, Tong S, Webb S, Higgins A, Ryan E, Venkatesh B, Roberts JA , Tran H, Zacharynski R, McFadyen J, Aung AK, Lawler P, Winearls J, Burrell A	HeIDI	Antithrombotic therapy to ameliorate clinical complications in community acquired pneumonia (ATTACC-CAP)	2023 Medical Research Future Fund (MRFF) International Clinical Trial Collaborations Round 2 (2035628)	\$2,484,939	4 years, 2024 – 2028
McQuilten Z, Petrie D, Hawkes E, Reynolds J, Crispin P, Fanning L, Weinkove R, Spencer A, Morrissey CO, Paterson DL, Wood E, Roberts JA , Stanworth S, Mulligan S, Opat S	HeIDI	Generating evidence to improve use of immunoglobulin replacement to reduce infections in blood cancers: The RATIONAL Platform Trial	2021 Medical Research Future Fund (MRFF) Optimising the Clinical Use of Immunoglobulins (MRF2018373)	\$3,984,139	5 years, 2022 – 2027
Milford E, Reade M , Wood E, McQuilten Z, French C, Litton E, Rickard C , Daly J, Flint A, Irving A, Wilkinson P, Wilson K, Mason A, Howe B, Trevor D	HeIDI, RBWH ICU	The Threshold for Platelets study: a prospective randomised controlled trial to define the platelet count at which critically ill patients should receive a platelet transfusion prior to an invasive procedure	MRFF Clinical Trials Activity	\$2.9M	2023 – 2027
Midori Nakagaki	HeIDI, Pharmacy	Microbiome-medication interactions and clinical outcomes in transplant and cellular therapy	Queensland Health Targeted Clinical Research Fellowship	\$125,000	2 years, 2025 – 2026
Peri A, Harris PNA	Infectious Diseases, HeIDI	Improved pathogen and antimicrobial resistance diagnostics in bloodstream infection and sepsis using a metagenomic approach (the META Study)	2025 RBWH Research Project Grant	\$50,000	2 years, 2025 – 2026
Rickard C	HeIDI, RBWH	The IVCare adaptive platform trial: Towards zero bloodstream infections in IV catheters.	NHMRC Investigator Grant Leadership 2	\$2.4M	2023 – 2027

Investigator Names (RBWH staff in bold)	RBWH Departments / Research Groups	Research Project Title	Granting Body	Total Awarded (whole all years)	Length of Awards in years and years active
Rickard C , Stewardson A, McQuilten Z, McGree J, Polkinghorne K, Schults J , Byrnes J, Lazarus B, Harris P , MacPhail A, Paterson D, Chopra V, Smith S, Mimos O, Buetti N	HeIDI, RBWH	Comparative effectiveness of Class II/III medical devices to prevent bloodstream infections in central venous catheters: The IVCare adaptive platform Trial	MRFF Clinical Trials Activity	\$5,000,000	2025 – 2029
Rickard C , Lovegrove J , Ball D , Harris P , Martin A	HeIDI, RBWH	Reducing blood culture contamination with the use of a needle-less blood draw device (PIVO Pro): An adaptive group sequential randomized controlled trial (The PIVO Trial)	Herston Infectious Diseases Institute Collaborative Research Grants 2024, supported by the RBWH Foundation	\$69,862	2025 – 2027
Rickard C , Lovegrove J , Ball D , Harris P , Martin A	HeIDI, RBWH	Reducing blood culture contamination with the use of a needle-less blood draw device (PIVO Pro): An adaptive group sequential randomized controlled trial (The PIVO Trial)	Becton Dickinson	Commercial in confidence	2025 – 2027
Rickard C , Schults J	HeIDI	Statewide Healthcare Acquired Infection Data Connectivity	Clinical Excellence Queensland Statewide Clinical Networks Project Funding	\$337,197	4 years, 2023 – 2027
Roberts JA	Infectious Diseases	Optimizing antibiotic dosing in the Staphylococcus aureus Network Adaptive Platform trial (O-SNAP)	Herston Infectious Diseases Institute (HeIDI) Collaborative Research Grants 2024	\$70,000	2 years, 2024 – 2026
Roberts JA , Slavin M, Paterson DL, Comans T, Lipman J , Landersdorfer C, Joynt G, Bellomo R, Clark J, Parker S	ICU	Centre of Research Excellence - REduce the burden of antimicrobial reSistance through oPtimal, persONalised Dosing (RESPOND)	National Health and Medical Research Council of Australia Centre for Research Excellence Grant (NHMRC APP2007007)	\$2,500,000	5 years, 2021 – 2025
Roberts JA , Alffenaar JW, Slavin M, Parker S, Lindsay J, Chatfield M, Irwin A, Cunich M, Roberts N, Selby P, Nakagaki M , Lai T, Legg A , Ungerer J.	Haematology	Pharmacogenomics for better treatment of fungal infections in cancer: The PRAGMATIC Study	2022 Medical Research Future Fund (MRFF) 2022 Quality, Safety and Effectiveness of Medicine Use by Pharmacists (MRFMMIP000040)	\$1,499,982	3 years, 2023 – 2026

Investigator Names (RBWH staff in bold)	RBWH Departments / Research Groups	Research Project Title	Granting Body	Total Awarded (whole all years)	Length of Awards in years and years active
Roberts JA	HeIDI	Translating precision antibiotic dosing into better outcomes for severe infections	National Health and Medical Research Council of Australia Investigator Grant – Leadership 2 (NHMRC APP2009736)	\$2,772,570	4 years, 2022 – 2026
Roberts JA , Nguyen A, Cotta MO, Ireland D, McCarthy K , Horvath R, Legg A .	HeIDI	Development and clinical integration of a novel precision dosing software application to improve antimicrobial dosing in critically ill patients.	Herston Infectious Diseases Institute (HeIDI) and CSIRO IDR and AMR Mission Affiliated Project Scheme	\$171,381	4 years, 2022 – 2025
Schembri M, Harris PNA , Henden A , Chan W, Burke A, Divithotawela C, Forde B, Schlebusch S, Phan MD, Edmunds K, Krause L, Jennison A, Roberts JA	HeIDI	Unlocking the gut microbiome to track the spread of AMR genes and pathogens	2023 Medical Research Future Fund (MRFF) Global Health Grant Initiative	\$1,990,643	5 years, 2024 – 2028
Schults J , Rickard C , Havers S , Russo P, Henderson B , Byrnes J, Smith S (consumer) , Hall L, Sullivan C, White N	HeIDI, RBWH, IPC	Reducing the Burden of Healthcare Associated Infection Using a Learning Health Systems Approach	NHMRC Collaborations in Health Services Research	\$1,000,000	2025 – 2027
Tognolini A , Eley V , Roberts JA	Anaesthetics	Plasma concentrations and outcomes of an optimised intraoperative lidocaine infusion regimen in patients with obesity	Australia and New Zealand College of Anaesthetists (26/027)	\$90,000	1 year, 2025
Wang J , Rickard C	HeIDI, RBWH	Evaluation of Chlorhexidine caps for central line associated bloodstream infection prevention in people needing Haemodialysis: A pilot randomised controlled trial	2026 RBWH Research Project Grant	\$69,862	2025 – 2026
Webb S, McArthur C, Totterdell J, Venkatesh B, Nichol A, McKenzie A, Tong S, Higgins A, Hammond N, Denholm J, Davis J, Roberts JA , McQuilten Z, Burrell A, Cheng A	HeIDI	A coordinated multiplatform randomised trial for hospitalised patients with COVID-19	2021 Medical Research Future Fund (MRFF) COVID-19 Treatment Access and Public Health Activities (MRF2016162)	\$3,997,914	5 years, 2022 – 2027

Investigator Names (RBWH staff in bold)	RBWH Departments / Research Groups	Research Project Title	Granting Body	Total Awarded (whole all years)	Length of Awards in years and years active
Wickins J, Marsh N, Morton L, Kasper K, August D, Rickard C	HeIDI, RBWH	Evaluating indwelling urinary catheter securement use and complications in adult inpatients: a mixed-methods study	RBWH SERTA	\$24,000	2025
Wood E, McQuilten Z, Petrie D, Bielby L, Fanning L, Burgner D, Roberts JA , van der Walt A, Heiss L, Daly J	HeIDI	OPTimising Immunoglobulin Management in Australia	National Health and Medical Research Council of Australia Centre for Research Excellence Grant (NHMRC APP2024876)	\$2,572,000	4 years, 2024 – 2028

RBWH Department / Research Group Led Research Activity

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
Karen Davies	Peter Donovan, Ian Coombes, Samantha Keogh, Jed Duff , Karen Hay, Dale Trevor	MN Implementation of the Medication Administration Evaluation and Feedback Tool (MAEFT): Knowledge Translation	Consultation	Nurses: 27 CKW, 23 TPCH, 85 Brighton, 229 RBWH, 34 STARS
Karen Davies	Peter Donovan, Ian Coombes, Samantha Keogh, Jed Duff , Karen Hay, Dale Trevor	Digital Evaluation and Implementation of the Medication Administration Evaluation and Feedback Tool (MAEFT) at STARS	Partnership	34 (nurses)
Karen Davies	Peter Donovan, Ian Coombes, Samantha Keogh, Jed Duff , Nicola Harper, Natasha Roberts, Melanie Duncan, Dale Trevor	Digital Evaluation and Implementation of the Medication Administration Evaluations and Feedback Tool (MAEFT) at STARS	Consultation	34 (Nurses)
Krispin Hajkowicz	Paul Chapman, Andrew Redmond	Defining the Infectome in Clinical Infectious Diseases Through Molecular and Metagenomic Analysis	Involvement	68
Krispin Hajkowicz	Colleen Lau, Kym Lowry, Charles Okafor, Daisy Lindsay, Georgina Peacock	An Observational Study of Epidemiology Burden of Disease and Genomics of Respiratory Syncytial Virus Infection in Older Adults of Queensland, Australia (RSV BoD-AU)	Involvement	2679
Josephine Lovegrove	Gillian Ray-Barruel, Emma Williams, Sally Havers, Jessica Schults, Sarah Joyce, Sarah Smith , Claire Rickard, Alice Bhasale, Diana Egerton-Warburton, Sarah Wiggs, Stephanie Hendry	Developing a national approach to monitoring peripheral intravenous catheter care quality	Consultation	N/A
Kate McCarthy	Angela White, Anoop Matthews	Patient solutions to the “problems” encountered in Hospital Isolation	Involvement	3
Kate McCarthy	Sally Havers, Gregory Merlo, Alison Pickering	Cost effective analysis of decolonisation of mMRSA inpatients post discharge	Consultation	Retrospective analysis – 38

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
Midori Nakagaki	Sarah Andersen, Andrea Henden, Glen Kennedy, Jacinta Smith, Jason Roberts et al	The effects of fibre supplementation and gastrointestinal microbiome on immunosuppressants in haematopoietic stem cell transplantation – a pharmacokinetic study (IMPACT PK)	Partnership	18
Claire Rickard	Daner Ball, Jessica Schults, Barbara Hewer, Glenda Hawley, Lauren Kearney, Nicole Marsh	Peripheral intravenous catheter insertion training for undergraduate dual degree nursing and midwifery students: A descriptive study	Not applicable	11 Students
Claire Rickard	Jue Wang, Jessica Schults, Eoin O'Sullivan, Tanu Taylor, Gabor Mihala	Evaluation of chlorhexidine caps for central line associated blood stream infection prevention in people needing haemodialysis: A Pilot Randomised Control Trial	Partnership	Recruitment commencing 2026
Jessica Schults	Kate McCarthy	Co-designing a clinical checklist with clinical end users	Partnership	N/A
Jessica Schults	HeIDI, Alison Pickering	Strengthening Hospital Associated Surveillance in QLD: A State-wide consensus project	Consultation	N/A
Jessica Schults	Joshua McRae, Sally Havers, Jodie Austin, Claire Rickard, Clair Sullivan, Tara Isaacs	Healthcare-associated infection tracking and connectivity and Health Informatics	Not applicable	N/A
Jessica Schults	Kate McCarthy, Claire Rickard, Sally Havers, Trish Hurst, Debra Vessey, Paul Simpson, Janine Geary, Daner Ball, Lisa Hall, Judith Jones	Characterisation of Intravascular Access Device (IVAD) Staphylococcus aureus Blood Stream Infection (SAB)	Partnership	N/A
Jessica Schults	Patrick Harris, Jason Roberts, Krispin Hajkowicz, Claire Rickard, Sally Havers, Kevin O'Callaghan, Stephanie Hendry, Bonnie Woods, Paul Simpson	The REcognising and reSPONDing to patients with BloodStream Infections (RESPOND-BSI) Study	Not applicable	N/A
Jessica Schults	Sally Havers, Claire Rickard, Lisa Hall, Clair Sullivan, Naomi Runnegar, Belinda Henderson, Julia Clark, Kim Edmunds, Daner Ball, Sarah Smith, Josephine Lovegrove, Alison Smtih, Paul Simpson, Alison Pickering, Janine Carrucan, Sarah Piere, Victoria Bruton, Olivia Sarri	Mapping hospital-associated infection surveillance across Queensland public hospitals: A descriptive study to identify practice variation across organisations	Not applicable	N/A
Jessica Schults	Alison Smith, Sally Havers, Janice Geary, Judith Jones, Debra Vasey, Paul Simpson, Alison Pickering, Kate McCarthy, Lisa Hall, Claire Rickard	Bloodstream infection under review: Codesigning a standardised approach to bloodstream infection in Queensland Health	Involvement	8

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
Amanda Gwee, Jason Roberts	Amy Legg , Steve Tong, Josh Davis, Marc Scheetz, Max Bloomfield, Andrea Kwa, Paul Williams, Eliza Milliken, Mark Chatfield, Matthew Pellan Cheng, Paul Chin, Mei Zhang, Nick Douglas, Susan Morpeth, Genevieve Walls, Richard Everts	Optimizing antibiotic dosing in the Staphylococcus aureus Network Adaptive Platform trial (O-SNAP)	Involvement	24
Jason Roberts	Luminita Vlad, Julian Lindsay, Johannes Alfenaar, Tony Lai, Monica Slavin, Catherine Liu, Mark Chatfield, Adam Irwin, Michelle Cunich, Natasha Roberts, Jacinta Smith, Phillip Selby, Midori Nakagaki , Amy Legg , Glen Kennedy , Jacobus Ungerer, Rachael Lawson	PhaRmAcogenoMics for better treatment of fungAI infections In Cancer (PRAGMATIC trial)	Consultation	7

Collaborative Research Activity Involving RBWH Department / Research Group

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
Josh Davis and Steven Tong	Bridget Barber , Andrew Redmond , Krispin Hajkowicz , Paul Chapman , Anna Hume , Alex Stewart , Michael Nissan , Bianca Graves , Jason Roberts	S. aureus Network Adaptive Platform Trial (SNAP)	Involvement	209
Victoria G. Hall	KY Yong, A Liu, Z Andrews, P Kinsella, N Laundry, J Wolfe, L Cooley, OC Smibert, A Thomas, M England, P Boan, G Peacock , D Lindsay , K Hajkowicz , E Liu, K Mitsakos, M Greenwood, M Barrios, K Wong, J Rose, E Xiong, M Roberts, S Alcantara, R Jayakumar, IW Liang En, MK Yong, MA Slavin, BW Teh	The RUSTIC study: Respiratory Virus Infection in a Contemporary Longitudinal Cohort of Patients with Haematological Malignancy	Consultation	40
Johan Maertens	Krispin Hajkowicz , Daisy Lindsay , Georgina Peacock , Angus Lane , Mark Fahmy , Ryan Perkins	Phase III, Adjudicator-blinded, Randomised Study to Evaluate Efficacy and Safety of Treatment With Olorofim Versus Treatment With AmBisome® Followed by Standard of Care in Patients With Invasive Fungal Disease Caused by Aspergillus Species (OASIS)	Consultation	2
Jonathan Iredell	Paul Chapman , Krispin Hajkowicz	Standardised treatment and monitoring protocol for adult and paediatric patients receiving bacteriophage therapy (STAMP)	Involvement	1

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
Kathy Petoumenos	Sumi Britton	Cohort of Australian women with HIV (CLIO)	Involvement	15
Ben Rogers	Patrick Harris	BALANCE +: A Platform Trial for Gram Negative Bloodstream Infections	Involvement	2
Joshua Davis, Laurens Manning	Paul Chapman, Jerry Van Der Poll	Randomised Arthroplasty infection worldwide multidomain adaptive platform trial (ROADMAP)	Involvement	2
Gail Matthews	Bridget Barber	Strategies and Treatments for Respiratory Infections and Viral Emergencies (STRIVE)	Involvement	1
James McMahon	Krispin Hajkowicz, Michael Lane	BOOST-IC – COVID-19 Vaccination in immunocompromised	Involvement	7
Michael Nissen	Michael Lane, Krispin Hajkowicz	Phase 2b, randomized, controlled, open-label study to evaluate the immune response and safety of the RSVPreF3 OA investigational vaccine in adults (≥18 years of age) when administered to lung and renal transplant recipients comparing 1 versus 2 doses and compared healthy controls (≥50 years of age) receiving 1 dose.	Involvement	13

Research Publications

Authors

Investigator	ORCID ID
Jason Roberts	https://orcid.org/0000-0001-6218-435X
Patrick Harris	https://orcid.org/0000-0002-2895-0345
Jessica Schults	https://orcid.org/0000-0002-5406-9519
Josephine Lovegrove	https://orcid.org/0000-0003-1466-2374
Claire Rickard	https://orcid.org/0000-0002-6341-7415
Daner Ball	https://orcid.org/0000-0002-9438-5428
Karen Davies	https://orcid.org/0000-0003-3510-5227
Sally Havers	https://orcid.org/0000-0001-6362-6412
Christine Brown	https://orcid.org/0009-0003-8050-3934
Gillian Ray-Barruel	https://orcid.org/0000-0001-8875-7523
Krispin Hajkowicz	https://orcid.org/0000-0001-6990-0486
Midori Nakagaki	https://orcid.org/0000-0003-4086-6960
Bridget Barber	https://orcid.org/0000-0003-1066-7960
Kate McCarthy	https://orcid.org/0000-0001-6173-9659

Publications in 2025

Journal Articles (RBWH staff or consumers in bold)

Coulon PML, Ramsay K, Lee A, Ritmejerite E, Pitt ME, To J, Mediati DG, Gassiep I, Reed S, **Harris PNA**, Myers GSA. Profiling of Burkholderia pseudomallei variants derived from Queensland's clinical isolates. Microbiol Spectr. 2025 Dec 30:e0243725. doi: 10.1128/spectrum.02437-25.

Coulon PML, Chowdhury PR, Gassiep I, Ramsay K, Lee A, Ritmejerite E, Pitt ME, To J, Reed S, **Harris PNA**, Myers GSA. Co-isolation of genetically distinct Burkholderia pseudomallei strains from a single patient in North Queensland. PLoS One. 2025 Dec 18;20(12):e0338333. doi: 10.1371/journal.pone.0338333.

Aslan AT, **Harris PNA**, Paterson DL. In reply to the letter to editor regarding "Comparison of ceftazidime-avibactam with other appropriate antimicrobial therapy for the treatment of OXA-48- or KPC-producing Enterobacterales infections in Türkiye: A multi-centre retrospective matched-cohort study". Int J Antimicrob Agents. 2025 Dec 11;67(2):107691. doi: 10.1016/j.ijantimicag.2025.107691.

Peri AM, **Harris PNA**, Banerjee R. Rapid Diagnostic Strategies for Antibiotic-Resistant Bacteria Causing Bloodstream Infection. Infect Dis Clin North Am. 2025 Dec 19:S0891-5520(25)00102-3. doi: 10.1016/j.idc.2025.11.008.

Paterson DL, Sulaiman H, Liu PY, Chatfield MD, Yilmaz M, Salmuna ZN, Mazlan MZ, Anunnatsiri S, Sirijatuphat R, Chotiprasitsakul D, Lye DC, Somani J, Kalimuddin S, Aslan AT, Thamlikitkul V, Lee YT, Yang YS, Lin YT, Ramli WNW, Tseng CH, Archuleta S, Chan YFZ, Forde BM, **Wright H**, Stewart AG, Ramsay KA, Ling W, Rossi V, Harris-Brown TM, **Harris PNA**; GAME CHANGER Trial Investigators. Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial. Lancet Infect Dis. 2026 Feb;26(2):148-159. doi: 10.1016/S1473-3099(25)00469-4.

Timsit JF, Ling L, de Montmollin E, Bracht H, Conway-Morris A, De Bus L, Falcone M, **Harris PNA**, Machado FR, Paiva JA, Paterson DL, Poulakou G, **Roberts JA**, Roger C, Shorr AF, Tabah A, **Lipman J**. Antibiotic therapy for severe bacterial infections. Intensive Care Med. 2025 Oct;51(10):1867-1885. doi: 10.1007/s00134-025-08063-0.

Keogh S, **Larsen EN**, **Edwards F**, Totsika M, **Marsh N**, **Harris PNA**, **Laupland KB**. Speciation of coagulase-negative staphylococci: A cohort study on clinical relevance and outcomes. Infect Dis Health. 2025 Nov;30(4):307-315. doi: 10.1016/j.idh.2025.04.001.

Lin C, Jennison AV, Leong LEX, Speers DJ, Meumann EM, Cooley L, Kennedy K, Arnott A, Winter D, Rawlinson W, Robson J, **Harris P**, Donald A, Seemann T, Ballard SA, Kirk M, Sintchenko V, Williamson DA, Howden BP; Communicable Diseases Genomics Network. Communicable diseases genomics network: promoting and harmonising pathogen genomics implementation for public health in Australia. Lancet Reg Health West Pac. 2025 Sep 22;63:101692. doi: 10.1016/j.lanwpc.2025.101692.

Walker LL, Phan MD, Permana B, Lian ZJ, Nhu NTK, Cuddihy T, Peters KM, Ramsay KA, Stewart C, Pfennigwerth N, Kidd TJ, **Harris PNA**, Paterson DL, Sweet MJ, Forde BM, Schembri MA. Emergence of a carbapenem-resistant atypical uropathogenic Escherichia coli clone as an increasing cause of urinary tract infection. Nat Commun. 2025 Sep 2;16(1):8200. doi: 10.1038/s41467-025-63477-0.

Permana B, Falconer C, Mayer-Coverdale J, Robson J, Cuddihy T, Schembri MA, Paterson DL, **Harris PNA**, Forde BM. Snapshot Genomic Surveillance Reveals Insights into Antimicrobial Resistance and Lineage Diversity of Uropathogens in Older Adults in Queensland. Open Forum Infect Dis. 2025 Sep 26;12(10):ofaf610. doi: 10.1093/ofid/ofaf610.

Gassiep I, Glover M, Beecham M, Gorman B, Page M, Stewart J, **Harris PNA**. Evaluation of an automated molecular diagnostic instrument for direct detection of Burkholderia pseudomallei from clinical specimens. J Med Microbiol. 2025 Sep;74(9):002074. doi: 10.1099/jmm.0.002074.

Aslan AT, Tanriverdi LH, Hernandez AV, Akova U, Kutluca K, Chan S, Coussement J, Manuel AGJ, Origüen J, Sabé N, **Harris PNA**, Akova M, Paterson DL. Effectiveness and Safety of Antibiotics in Kidney Transplant Recipients With Asymptomatic Bacteriuria: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Open Forum Infect Dis. 2025 Aug 19;12(9):ofaf502. doi: 10.1093/ofid/ofaf502.

Ravi C, Irwin AD, **Harris PNA**. Probe-capture targeted next-generation sequencing: A novel approach for pathogen and antimicrobial resistance detection in sepsis. Clin. Transl. Disc., 5: e70079. https://doi.org/10.1002/ctd2.70079

Stewart AG, **Laupland KB**, **Edwards F**, Koo S, Hammond SP, **Harris PN**, Paterson DL, Slavin MA, Chen SC. Population-based longitudinal study over two decades of Candida and Candida-like species bloodstream infection reveals gender and species differences in mortality, recurrence and resistance. J Infect. 2025 Jul;91(1):106513. doi: 10.1016/j.jinf.2025.106513.

Subedi S, **Harris PNA**, Hall L, Paterson DL. Practical considerations for implementation of syndromic panel and diagnostic stewardship in the era of syndromic panel testing. Clin Microbiol Infect. 2025 Nov;31(11):1822-1827. doi: 10.1016/j.cmi.2025.06.013.

Subedi S, **Harris PN**, **Chapman P**, Chen AF, Davis JS, Liu PY, Marais LC, Salles MJ, **Roberts JA**, Rodriguez-Bano J, Wouthuyzen-Bakker M, Paterson DL, Benito N. A global survey of diagnostic practices in prosthetic joint infections. Diagn Microbiol Infect Dis. 2025 Oct;113(2):116919. doi: 10.1016/j.diagmicrobio.2025.116919.

Rafiei N, Subedi S, **Harris PN**, Paterson DL. Clinical and cost implications of Biofire FilmArray® meningitis / encephalitis panel testing: a systematic review. Diagn Microbiol Infect Dis. 2025 Jul;112(3):116823. doi: 10.1016/j.diagmicrobio.2025.116823.

Journal Articles (RBWH staff or consumers in bold)

- Laupland KB**, Stewart AG, Edwards F, **Harris PNA**, Coulter S. Community-onset bloodstream infection among people with opioid use disorders: a twenty-year population-based cohort study in Queensland, Australia. *Infect Dis (Lond)*. 2025 Jul;57(7):669-675. doi: 10.1080/23744235.2025.2471823.
- Ullman AJ**, **August D**, Kleidon TM, Walker RM, **Marsh N**, Bulmer AC, Pearch B, Runnegar N, Leema J, Lee-Archer P, Biles C, Gibson V, Royle R, Southam K, Byrnes J, Chopra V, Coulthard A, Mollee P, **Rickard CM**, **Harris PNA**, Ware RS. A Comparison of Peripherally Inserted Central Catheter Materials. *N Engl J Med*. 2025 Jan 9;392(2):161-172. doi: 10.1056/NEJMoa2406815.
- Aslan AT, Kara E, Köksal G, Bilir Y, Saraçoğlu KT, Eser F, Güner R, Alkan S, D'Avino A, Escudero-Sanchez R, Kutluca K, Kaya SY, Saltoğlu N, Loiacono L, Coladonato S, Del Giacomo P, Cascio A, Pallotto C, Francisci D, Öztürk B, Pinar A, Dağ O, **Harris PNA**, Paterson DL, Akova M. Comparison of piperacillin-tazobactam and vancomycin (TZP-VAN) with piperacillin-tazobactam and teicoplanin (TZP-TEI) for the risk of acute kidney injury (CONCOMITANT): A prospective observational, multinational, multi-centre cohort study. *Int J Antimicrob Agents*. 2025 Mar;65(3):107446. doi: 10.1016/j.ijantimicag.2025.107446.
- Stewart AG, **Harris PNA**, Graham RMA, Jennison AV, Schlebusch S, Kakkanat A, Harris-Brown T, Paterson DL, Forde BM. Differences in antimicrobial resistance gene abundance and microbial diversity of the gut microbiome in patients on antibiotics enrolled in a clinical trial. *Ther Adv Infect Dis*. 2025 Jun 5;12:20499361251337597. doi: 10.1177/20499361251337597.
- Stewart AG, **Harris PNA**, Edwards F, Kiani B, Paterson DL, **Laupland KB**. *Klebsiella pneumoniae* species complex bloodstream infection in adult patients: changing epidemiology and determinants of poor outcomes. *Infection*. 2025 Jun;53(3):1179-1187. doi: 10.1007/s15010-024-02457-w.
- Sundermann AJ, Rosa R, **Harris PNA**, Snitkin E, Javaid W, Moore NM, Hayden MK, Allen K, Rodino K, Peacock SJ, Abbo LM, Harrison LH. Pathogen genomics in healthcare: overcoming barriers to proactive surveillance. *Antimicrob Agents Chemother*. 2025 Jan 31;69(1):e0147924. doi: 10.1128/aac.01479-24.
- Edwards F, Edwards KH, Tabah A, **Harris PNA**, **Laupland KB**. Differentiation of *Providencia* species bloodstream infections: A population-based analysis. *Diagn Microbiol Infect Dis*. 2025 Jan;111(1):116602. doi: 10.1016/j.diagmicrobio.2024.116602.
- Davidson N, Lowry K, Parmar BV, Robertson T, Gupta R, **Harris P**, Whitley D. 2025. A perplexing diagnosis: role of real-time PCR for diagnosis of *Haycocknema perplexum*. *Pathology Update* 2025. Melbourne, VIC Australia, 21-23 February 2025. Oxford, United Kingdom: Elsevier. Doi: 10.1016/j.pathol.2024.12.378.
- Gamage GP, **Lovegrove J**, Seneviratne S, Tobiano G, Gillespie BM. Postoperative Wound Care Practices of Acute Care Nurses: An Integrative Review. *Int Wound J*. 2025 Nov;22(11):e70781. doi: 10.1111/iwj.70781.
- Ball DL**, **Ray-Barruel G**, **Hewer B**, Hawley G, **Kearney L**, **Schults JA**, **Marsh N**, **Rickard CM**. Peripheral intravenous catheter insertion training for undergraduate dual degree nursing and midwifery students: A descriptive study. *Aust J Adv Nurs*. 2025 Dec. 22;42(4). doi: 10.37464/2025.424.2182
- Rickard CM**, **Schults J**, Mihala G, **Larsen E**, **Marsh N**, Runnegar N, Kleidon T, Ullman AJ, **Keogh S**, **Ball D**, **Corely A**, Bugden S, **Ray-Barruel G**. Infection risk of peripheral intravenous catheters: meta-synthesis of 18 prospective studies with 14,606 catheters. *Antimicrob Resist Infect Control*. 2025 Oct 27;14(1):129. doi: 10.1186/s13756-025-01645-z.
- Schults JA**, **Havers SM**, **Henderson BC**, **Healy S**, Runnegar N, **Hurst T**, Charles K, **Smith A**, Clark JE, Birch R, Campbell J, Carrucan J, Gamlin J, Geary J, Heather CS, MacBeth DA, Maxwell K, Simpson P, **Smith S**, **Lovegrove J**, **Ball D**, Hall L, **Rickard CM**. Expert consensus and recommendations for health care-associated infection surveillance in Queensland, Australia: A modified Delphi study. *American J Infection Control*. 2025 53(8):849-854. doi: 10.1016/j.ajic.2025.02.012.
- Havers SM**, **Rickard CM**, **Lovegrove J**, Stewardson AJ, Egerton-Warburton D, McCann RL, **Ray-Barruel G**, **Davies KM**, **Brown C**, Mathias SM, **Schults JA**. Infection prevention and control priorities to improve peripheral intravenous catheter care – setting a national priority agenda. *Infect Dis Health*. 2025 Jul 28;31(1):100379. doi: 10.1016/j.idh.2025.07.001.
- Marsh N**, **O'Brien C**, **Larsen EN**, Alexandrou A, Ware RS, **Pearse I**, **Coyer F**, Patel MS, Royle R, **Rickard CM**, Sosnowski K, **Harris PNA**, **Laupland KB**, Bauer MJ, Fraser JF, McManus C, Byrnes J, **Corley A**. Securing jugular central venous catheters with dressings fixed to a liquid adhesive to prevent dressing failure in intensive care patients (the STICKY Trial): a randomised controlled trial. *Crit Care Med*. 2025 Feb 1;53(2):e282-e293. doi: 10.1097/CCM.0000000000006533.
- Marsh N**, **Larsen E**, **O'Brien C**, Young ER, **Peach H**, **Corley A**, Ullman A, **Keogh S**, **Rickard CM**, Bulmer A, Ware R. Optimal catheter-to-vein ratios to prevent peripheral venous catheter failure: a single-centre prospective cohort study. *Br J Anaesth*. 2025 Oct;135(4):1106-1108. doi: 10.1016/j.bja.2025.06.037.
- Xu HG**, Campbell J, Takashima M, **Larsen E**, Coyer F, **August D**, Dean A, Pitt C, Griffin B, **Marsh N**, **Rickard CM**, Ullman A. Development and Preliminary Validation of a Central Venous Access Device-Associated Skin Impairment Classification Tool Using Modified Delphi and Clinimetric Methods. *J Adv Nurs*. 2025 Feb;81(2):1095-1112. doi: 10.1111/jan.16416.
- Gillespie BM, Tobiano G, **Lovegrove J**, Sugathapala RDUP, Thalib L, Liang R, Walker R, Erickson A, Carlini J, Thong S, Addy K, Spencer M, Chaboyer W. Effect of Enhanced Recovery After Surgery programs on surgical site infection and 30-day readmission in patients undergoing gastro-intestinal procedures: An umbrella review. *Int J Nurs Stud*. 2026 Mar;175:105315. doi: 10.1016/j.ijnurstu.2025.105315.
- Fulbrook P, McAllister R, Weatherburn C, Burke E, **Lovegrove J**. Evaluation of a Pressure Injury Prevention Bundle in an Australian Intensive Care Unit: A Before and After Study. *Nurs Crit Care*. 2025 Nov;30(6):e70242. doi: 10.1111/nicc.70242.
- Fulbrook P, **Lovegrove J**, Ven S, Schnaak S, Nowicki T. Use of a risk-based intervention bundle to prescribe and implement interventions to prevent pressure injury: An observational study. *J Adv Nurs*. 2025 Sep;81(9):5315-5328. doi: 10.1111/jan.16309.

Journal Articles (RBWH staff or consumers in bold)

Ven S, Fulbrook P, Burston A, **Lovegrove J**, Miles SJ. Pressure injury risk assessment for palliative care patients in the acute hospital setting: a scoping review. *BMC Palliat Care*. 2025 Jul 25;24(1):212. doi: 10.1186/s12904-025-01842-y.

Tobiano G, Liang R, Chaboyer W, **Lovegrove J**, Addy K, Gillespie BM. Clinicians' views on implementing enhanced recovery after surgery: a descriptive qualitative study. *ANZ J Surg*. 2025 Jan-Feb;95(1-2):240-246. doi: 10.1111/ans.19342.

Lovegrove J, Fulbrook P, Yuan C, Lin F, Liu XL. The Chinese Mandarin COMHON Index and Braden Scale to assess pressure injury risk in intensive care: An inter-rater reliability and convergent validity study. *Aust Crit Care*. 2025 Jan;38(1):101093. doi: 10.1016/j.aucc.2024.05.015.

Cobos-Vargas A, Fulbrook P, **Lovegrove J**, Acosta-Romero M, Camado-Sojo L, Colmenero M. Implementation of a risk-stratified intervention bundle to prevent pressure injury in intensive care: A before-after study. *Aust Crit Care*. 2025 Mar;38(2):101123. doi: 10.1016/j.aucc.2024.09.008.

Dugeon B, **Schults JA**, **Ray-Barruel G**, **Xu GH**, **Ball D**, Yasuda H, Dugeon R, Mercier J, Mihala G, Barker N, Mimos O, **Rickard CM**. Infrared Devices Versus Traditional Palpation Approach for Peripheral Intravenous Catheter Insertion in Adults: A Systematic Review and Meta-Analysis. *J Adv Nurs*. 2026 Feb;82(2):1775-1790. doi: 10.1111/jan.17007.

Charles KR, Dow B, **Schults JA**, Stocker C, Anthony L, Minogue J, Gibbons KS, Long D. Family Functioning and Parent Behavioural Changes Post-Admission to the Paediatric Intensive Care Unit: A Single-Centre Cohort Study. *Nurs Crit Care*. 2025 Nov;30(6):e70182. doi: 10.1111/nicc.70182.

Schults JA, Wu Y, Snelling T, Pérez Chacón G, **Ball D**, Charles K, Marsh J, McLeod C, Yasuda H, **Rickard CM**. Central venous catheter infections: building a causal model with expert domain knowledge to inform future clinical trials. *Antimicrob Resist Infect Control*. 2025 Oct 8;14(1):116. doi: 10.1186/s13756-025-01630-6.

Rickard CM, Stewardson AJ, **Havers SM**, Buetti N, Polkinghorne KR, MacPhail A, McQuilten Z, Lazarus B, Charles KR, **Schults JA**; IVCare Trial Study Group. Interventions to prevent bloodstream infections associated with central venous access devices: Priorities for an adaptive platform trial. *Am J Infect Control*. 2025 Sep;53(9):1004-1007. doi: 10.1016/j.ajic.2025.06.003.

Dugeon B, **Rickard CM**, **Schults JA**, Guenezan J, Mimos O. Chlorhexidine and povidone-iodine: Unmasking the unknown in catheter-related infection prevention, a narrative review. *J Infect Public Health*. 2025 Sep;18(9):102851. doi: 10.1016/j.jiph.2025.102851.

Schults JA, **Smith A**, **Havers SM**, Mitchell BG, Kwong JC, Russo PL, Stewardson AJ, **Rickard CM**. Government funding for healthcare infection prevention research: A scoping review of the past decade. *Infect Dis Health*. 2025 Nov;30(4):353-357. doi: 10.1016/j.idh.2025.05.003.

Curlis J, Charles KR, Royle R, **Rickard CM**, **Ball D**, Rahiman S, **Schults JA**. Endotracheal Tube-Associated Complications in Paediatric Critical Care: A Systematic Review and Meta-Analysis. *Nurs Crit Care*. 2025 Jul;30(4):e70066. doi: 10.1111/nicc.70066.

Yasuda H, **Rickard CM**, **Schults JA**, **Marsh N**, Kashiura M, Kishihara Y, Shinzato Y, Amagasa S, Moriya T, Kotani Y, Kondo N, Sekine K, Shime N, Morikane K, Abe T; AMOR-VENUS Study Group. Impact of Noradrenaline Administration Dosage on the Occurrence of Peripheral Intravenous Catheter-Related Venous Phlebitis in Critically Ill Patients Using a Time-Dependent Multilevel Cox Regression Model. *Emerg Med Int*. 2025 May 6;2025:4457109. doi: 10.1155/emmi/4457109.

Kleidon TM, Takashima M, **Rickard CM**, **Schults JA**, Bulmer AC, Ullman AJ. A Prospective Cohort Study of Technique and Technology Used to Improve First Time PIVC Insertion Success in Hospitalised Paediatric Patients. *J Adv Nurs*. 2025 Oct;81(10):6486-6503. doi: 10.1111/jan.16795.

Schults JA, Hall L, Charles KR, **Rickard CM**, Le Marsney R, Ergetu E, Gregg A, Byrnes J, Rahiman S, Long D, Lake A, Gibbons K. Hospital-Acquired Complications in Critically Ill Children and PICU Length of Stay, Duration of Respiratory Support, and Economics: Propensity Score Matching in a Single-Center Cohort, 2015-2020. *Pediatr Crit Care Med*. 2025 Mar 1;26(3):e304-e314. doi: 10.1097/PCC.0000000000003668.

Kleidon TM, **Schults JA**, Royle RH, Gibson V, Ware RS, Andresen E, Cattanach P, Dean A, Pitt C, Ramstedt M, Byrnes J, Nelmes P, **Rickard CM**, Ullman AJ. First-Attempt Success in Ultrasound-Guided vs Standard Peripheral Intravenous Catheter Insertion: The EPIC Superiority Randomized Clinical Trial. *JAMA Pediatr*. 2025 Mar 1;179(3):255-263. doi: 10.1001/jamapediatrics.2024.5581.

Kuek M, McLean SK, Palombo EA, Brownie S, **Rickard CM**, Choudhury N. Evaluating the efficacy of disinfectant agents and application times for vascular catheter needleless connector decontamination. *Infect Dis Health*. 2025 Oct 21;31(2):100392. doi: 10.1016/j.idh.2025.09.005.

Lovegrove J, **Havers S**, **Smith A**, **Ball DL**, Ullman AJ, Bhasale A, **Rickard CM**. Peripheral intravenous catheter policies and procedures across Queensland: a document review and analysis of underpinning evidence and alignment with clinical standards. *Aust Health Rev*. 2025 Dec 4;49(6):AH25234. doi: 10.1071/AH25234.

Lovegrove J, **Havers S**, **Schults J**, **Ray-Barruel G**, Bhasale A, **Keogh S**, Smith S, Fritts J, Ullman AJ, **Xu HG**, **Rickard CM**. Does policy and practice for peripheral intravenous catheters match clinical standards? A point prevalence study. *Infect Dis Health*. 2025 Oct 18;31(2):100391. doi: 10.1016/j.idh.2025.09.004.

Havers SM, **Rickard CM**. Rethinking the world of vascular access management with a focus on collaboration. *Enferm Clin (Engl Ed)*. 2025 Jun-Jul;35(4):502334. doi: 10.1016/j.enfcl.2025.502334. Invited editorial.

Journal Articles (RBWH staff or consumers in bold)

Egerton-Warburton D, Kuhn L, Enticott J, Yang SN, Buntine P, Callander E, Cullen L, Fatovich D, Hullick C, Heiss L, Keijzers G, Le LK, Mihalopoulos C, Morphet J, O'Reilly G, Pokhrel B, **Rickard C**, Tran V, Cameron P, Teede HJ. Implementing best practice for peripheral intravenous cannula use in Australian emergency departments: a stepped-wedge cluster-controlled trial and health economic analysis protocol. *BMJ Open*. 2025 Jun 16;15(6):e096962. doi: 10.1136/bmjopen-2024-096962.

Eley V, Peters N, Woods C, Llewellyn S, **Derboghossian T, Ogg M, Rickard CM, Chin A**. Perioperative arterial catheterization: A prospective evaluation of ultrasound, infection, and patient-focused outcomes. *J Vasc Access*. 2025 May;26(3):837-845. doi: 10.1177/11297298241246300.

Barton G, **Rickard CM, Roberts JA**. Considerations for β -lactam antimicrobial continuous infusion. Authors' reply to Massart et al. and Marzaroli et al. *Intensive Care Med*. 2025 Jan;51(1):230-231. doi: 10.1007/s00134-024-07724-w.

Durgeon B, **Rickard CM, Peters N**, Chopra V, Mimos O. Procedural and Therapy Peripheral Intravenous Catheters: A Framework for Safety, Quality and Patient-Centred Care. *J Adv Nurs*. 2025 Nov 3. doi: 10.1111/jan.70347.

Xu H, Bowdery J, To Y, **Duff J**, Griffin B, Ullman AJ, **Rickard CM**, Plummer K. Peripheral intravenous catheter clinical care standard adherence in emergency departments: A qualitative study underpinned by the behaviour change wheel. *J Adv Nurs*. 2025 Nov;81(11):7659-7673. doi: 10.1111/jan.16409.

Xu HG, Doubrovsky A, **Rickard CM**, Rockliff L, Tang C, Ullman AJ. Peripheral Intravenous Catheter Care at Australian Emergency Departments: A Cross-Sectional Observational Study. *J Adv Nurs*. 2025 Dec;81(12):8597-8607. doi: 10.1111/jan.16810.

Keogh S, Edwards F, Levido A, Alexandrou E, **Corley A**, Coyer F, **Dhanani J**, Gibbons K, Hammond NE, Knowles S, **Laupland KB, Ramanan M, Rickard CM**, Udy A; George Institute for Global Health and the Australian and New Zealand Intensive Care Society Clinical Trials Group. The prevalence and use of arterial catheters in adult intensive care units: An Australian and New Zealand point prevalence study. *Aust Crit Care*. 2025 Nov;38(6):101312. doi: 10.1016/j.aucc.2025.101312.

Keogh S, Larsen E, Corley A, Takashima M, **Marsh N**, Edwards M, **Reynolds H, Dhanani J, Coyer F, Laupland KB, Rickard CM**. Arterial catheter outcomes in intensive care: An analysis of 1117 patients. *Infect Dis Health*. 2025 Feb;30(1):12-17. doi: 10.1016/j.idh.2024.07.006.

Roberts JA, Heffernan AJ, Chai MG, **Harris PNA, Legg A**, Farkas A, **Laupland K, Dhanani J, Fourie C, Murray L**, Abdul-Aziz MH, Ungerer J, McWhinney B, **Lipman J, Cotta MO**. Resistance Optimised Antibiotic Dosing (The ROAD Study): Is dosing of meropenem and piperacillin-tazobactam optimised to prevent the emergence of antibiotic resistance safe and feasible in the ICU? A pilot study. *CMI Communications*. 2025 2(1). doi.org/10.1016/j.cmicom.2024.105051.

Nakagaki M, Hajkowicz K, Roberts JA, Henden AS. Cause and effect? A review of the impact of antibiotics on the gut microbiome in patients undergoing hematopoietic stem cell transplantation. *Expert Rev Anti Infect Ther*. 2025 Oct;23(10):863-876. doi: 10.1080/14787210.2025.2527970.

O'Keefe K, Denny KJ, Le Marsney R, McCullough J, Gilholm P, Budai KA, Béranger A, Lódi C, Obeidat M, Ragonnet G, Wacharachaisurapol N, **Roberts JA**, Gibbons KS, Raman S. Prolonged Versus Intermittent Beta-Lactam Antibiotic Infusions in Paediatric Critical Care: A Systematic Review and Meta-Analysis. *J Paediatr Child Health*. 2025 Dec 27. doi: 10.1111/jpc.70275.

Cairns KA, Hernandez-Mitre MP, Peel TN, Abbott IJ, Kaye DM, Marasco S, Daly D, Warner V, Coldham A, Pope JD, Schneider HG, Dooley MJ, Liu X, **Roberts JA**, Udy AA. A Pharmacokinetic Analysis of Intravenous Fluconazole in Adult Patients Undergoing Mechanical Circulatory Support Device Implantation. *Clin Pharmacokinet*. 2025 Dec 22. doi: 10.1007/s40262-025-01607-z.

Boast A, **Legg A**, McCarthy J, **Roberts JA**, Tong SY, Duffull S, Gwee A. Effect of ibuprofen on the pharmacokinetics of intravenous flucloxacillin in healthy adults. *Int J Antimicrob Agents*. 2025 Dec 1;67(2):107684. doi: 10.1016/j.ijantimicag.2025.107684.

McQuilten Z, O'Sullivan MVN, Purcell D, Edler P, Meagher N, Alcorn K, Bowen A, Daly J, Foo H, Goulding S, Gosbell I, Hammond N, Hills T, Hoar V, Jha V, Lim LL, McPhee G, Molton J, Morpeth S, Nguyen V, Paterson D, Rees M, **Roberts J**, Rogers BA, **Stewart A**, Sasadeusz J, Snelling T, Venkatesh B, Wood E, Davis JS, Tong SYC, Price DJ, Denholm JT. Convalescent plasma in hospitalised patients with COVID-19. *Intern Med J*. 2025 Dec;55(12):2024-2032. doi: 10.1111/imj.70253.

Vuong ML, Elkayal O, Van Daele R, Alfenaar JC, Stocker SL, **Roberts JA**, Debaveye Y, Wauters J, Mertens B, Boonstra JM, Sandaradura I, Marriott DJE, Brüggemann RJ, Schouten JA, Bergner R, Buijk S, Spriet I, Dreesen E. A fluconazole population pharmacokinetics study to improve target attainment in critically ill patients. *Infection*. 2025 Oct 14. doi: 10.1007/s15010-025-02663-0.

Sulaiman H, Rozali MA, Adiraju SKS, Hasan MS, Jamal JA, Liu X, Mat-Nor MB, Mazlan MZ, Othman-Jailani MI, Salmuna ZN, Wallis SC, **Roberts JA**, Abdul-Aziz MH. Meropenem dosing optimization on day 1 and steady state in critically ill patients without significant renal impairment. *Sci Rep*. 2025 Oct 29;15(1):37781. doi: 10.1038/s41598-025-20630-5.

Xu JH, Salman S, Morgan DJ, Won H, Wallis SC, Dyer J, **Roberts JA**, Rawlins MD. Cefazolin pharmacokinetics during prolonged intermittent kidney replacement therapy. *Anaesth Intensive Care*. 2025 Dec 8;310057X251396229. doi: 10.1177/0310057X251396229. Epub ahead of print.

Cree ML, Abdul-Aziz MH, Haisz E, Wallis SC, Won H, Sumi CD, Marjanovic D, Ordóñez JL, Schlapbach LJ, **Roberts JA**. The Impact of an Ex Vivo Pediatric Extracorporeal Membrane Oxygenation Circuit on Sequestration of Antimicrobials. *Crit Care Explor*. 2025 Oct 30;7(11):e1338. doi: 10.1097/CCE.0000000000001338.

Journal Articles (RBWH staff or consumers in bold)

Benavent E, Lora-Tamayo J, Uldemolins M, Pons-Oltra P, Gregoire M, Mancheño-Losa M, Hernández-Jiménez P, Meléndez-Carmona MÁ, Casals V, **Roberts JA**, Rigo-Bonnin R, Murillo O. Efficacy, safety, and population pharmacokinetics of a single 1500mg dose of dalbavancin for short-term therapy in patients with chronic prosthetic joint infections. *Antimicrob Agents Chemother*. 2025 Dec 10;69(12):e0077325. doi: 10.1128/aac.00773-25.

Mu Y, Yan K, McManus DP, Nguyen W, Rawle DJ, **Roberts JA**, Jones MK, Cai P. Marginal cytokine modulation by *Schistosoma mansoni* soluble egg antigen in SARS-CoV-2-infected K18-hACE2 mice. *Folia Parasitol*. 2025 Jun 16;72:2025.019. doi: 10.14411/fp.2025.019.

Cheng V, Suna J, Liu X, Moloney G, Marathe SP, Parker S, Ungerer JPJ, McWhinney B, Venugopal P, Alphonso N, **Roberts JA**. Population pharmacokinetics of cefazolin administered as prophylaxis in paediatric patients undergoing cardiac surgery. *Anaesth Crit Care Pain Med*. 2025 Oct 29;101653. doi: 10.1016/j.accpm.2025.101653.

Hernández-Mitre MP, Wallis SC, Loutit JS, Griffith DC, **Roberts JA**. Phase 1, randomized, double-blind, placebo-controlled, ascending single- and multiple-dose study of the safety, tolerability, and pharmacokinetics of intravenous xeruboractam (QPX7728) in healthy adult subjects. *Antimicrob Agents Chemother*. 2025 Oct;69(10):e0078425. doi: 10.1128/aac.00784-25.

Roberts JA, Uldemolins M, Liu X, Baptista JP, Bilgrami I, Boidin C, Brinkmann A, Castro P, Choi G, Cole L, De Waele JJ, Deans R, Donnellan S, Eastwood GM, Frey OR, Goutelle S, Gresham R, Jamal JA, Joynt GM, Kanji S, Kluge S, König C, Koulouras VP, **Lassig-Smith M**, Laterre PF, Lee A, Lefrant JY, Lei K, Leung P, Llauro-Serra M, Martin-Loeches I, Nor MBM, Mudaliar Y, Ostermann M, Paul SK, Peake SL, Rello J, Roberts DM, Roberts MS, Richards B, Rodríguez A, Roehr AC, Roger C, Seoane L, Sinnollareddy M, Sousa E, Soy D, Spring A, **Starr T**, Stephens D, Taccone FS, Thomas J, Turnidge J, Valkonen M, Varghese JM, Wallis SC, Walker RJ, Williams T, Wilson LC, Wittebole X, Wright DFB, Zikou XT, Bellomo R, **Lipman J**; SMARRT Study Collaborators. Meropenem and piperacillin/tazobactam optimised dosing regimens for critically ill patients receiving renal replacement therapy. *Intensive Care Med*. 2025 Sep;51(9):1628-1640. doi: 10.1007/s00134-025-08067-w.

Zaghi I, Cricca M, **Roberts JA**, Brandolini M, Colosimo C, Montanari S, Sambri V, Lewis RE. Development of blood culture time-to-positivity as a pharmacodynamic indicator for monitoring antibiotic therapy against MDR Gram-negative bacteria. *J Antimicrob Chemother*. 2025 Oct 3;80(10):2705-2713. doi: 10.1093/jac/dkaf276.

Morales Castro D, Al-Fares AA, Paternoster G, Lyster H, Hohlfelder B, Arias Ortiz J, Abdul-Aziz MH, Herr D, Alraish R, Ferre Contreras A, Palavecino M, Milella L, Watt K, Alkazemi A, Carini FC, **Roberts JA**, Riera Del Brio J, Pau Parra A, Kakar V, Dureau P, Duceppe MA, Alm M, Cha S, Shekar K, Dzierba AL; Extracorporeal Membrane Oxygenation Pharmacology Network (ECMOPharm Net). Pharmacological Research Agenda on Adult Extracorporeal Membrane Oxygenation Using the Delphi Method: A Position Paper of the Extracorporeal Membrane Oxygenation Pharmacology Network. *Crit Care Med*. 2025 Nov 1;53(11):e2246-e2260. doi: 10.1097/CCM.0000000000006806.

Li Y, **Roberts JA**, Abdul-Aziz MH, Sime FB. Continuous or extended vs intermittent infusions of beta-lactam antibiotics in ICU patients with pneumonia: a systematic review and meta-analysis of randomized controlled trials. *Antimicrob Agents Chemother*. 2025 Oct;69(10):e0073225. doi: 10.1128/aac.00732-25.

Raman S, Reddy R, De Souza DC, Cox R, Le Marsney R, Nallasamy K, Ramnarayan P, **Roberts JA**, Schlapbach LJ, Gibbons KS. Beta-lactam antibiotic administration in critically ill children with sepsis: an international survey of current practice. *Intensive Care Med*. – Paediatr. Neonatal 3, 18 (2025). doi.org/10.1007/s44253-025-00075-4.

Wolie ZT, Unwin S, Burke A, Won H, Wallis SC, Seaton RA, Gilchrist M, **Roberts JA**, Sime FB. Evaluation of the stability of tigecycline in elastomeric infusion devices used for outpatient parenteral antimicrobial therapy. *JAC Antimicrob Resist*. 2025 May 13;7(3):dlaf074. doi: 10.1093/jacamr/dlaf074.

Wolie ZT, **Roberts JA**, López-Cortés LE, Mirón-Rubio M, Pollard J, Marizan Nor AN, Abdul-Aziz MH, Jamieson C, Seaton RA, Gilchrist M, Sime FB. Current practices in outpatient parenteral antimicrobial therapy programmes: an international multi-centre survey. *JAC Antimicrob Resist*. 2025 May 27;7(3):dlaf075. doi: 10.1093/jacamr/dlaf075.

Xu JH, Cheng V, Rawlins M, Morgan D, Won H, Wu X, Dyer J, **Roberts JA**. Pharmacokinetics of Metronidazole During Prolonged Intermittent Kidney Replacement Therapy. *Hemodial Int*. 2025 Oct;29(4):713-716. doi: 10.1111/hdi.13242.

Götz KM, Kreuer S, Volz A-K, Parker SL, **Roberts JA**, Dimopoulos G, Dimski T, Kindgen-Milles D, Beuche LK, Kielstein JT, Lehr T. Population pharmacokinetics of intravenous fosfomycin: dose optimization for critically ill patients with and without kidney replacement therapy. *Antimicrob Agents Chemother*. 2025 Jun 4;69(6):e0177924. doi: 10.1128/aac.01779-24.

Tu Q, Won H, Sime FB, Raman S, Cotta MO, Wallis SC, Marjanovic D, Stacey S, Schlapbach L, **Roberts JA**. The FUSION Study: compatibility of antibiotics with commonly used medication infusions in a paediatric intensive care unit. *Eur J Hosp Pharm*. 2025 Apr 9;ejhpharm-2024-004450. doi: 10.1136/ehpharm-2024-004450.

Robson C, Liu X, Al-Mukhtar O, Wallis SC, Won H, Ordonez J, Gooley R, Stuart RL, Nicholls SJ, **Roberts JA**, Rogers BA. Population pharmacokinetics and optimized prophylaxis dosing of cefazolin during transcatheter aortic valve implantation. *J Antimicrob Chemother*. 2025 Jun 3;80(6):1604-1612. doi: 10.1093/jac/dkaf108.

Nix DE, Sime F, **Roberts JA**. Correction of posaconazole concentrations for hypoalbuminemia. *Pharmacotherapy*. 2025 Jun;45(6):324-331. doi: 10.1002/phar.70021.

Eley VA, Navarro S, Martin E, **Amoako A**, Hartel G, **Woods C**, Lu Y, **Lipman J**, **Roberts J**, Tang M, **Callaway L**. Cefazolin versus placebo for surgical antibiotic prophylaxis in low-risk cesarean delivery: a feasibility blinded randomized controlled trial. *BMC Pregnancy Childbirth*. 2025 Mar 26;25(1):353. doi: 10.1186/s12884-025-07484-5.

Journal Articles (RBWH staff or consumers in bold)

Mohammed SA, **Roberts JA**, Mirón-Rubio M, López Cortés LE, Assefa GM, Pollard J, **McCarthy K**, Gilchrist M, Cotta M, Sime FB. Quantifying cost savings from outpatient parenteral antimicrobial therapy programme: a systematic review and meta-analysis. *JAC Antimicrob Resist*. 2025 Apr 8;7(2):dlaf049. doi: 10.1093/jacamr/dlaf049.

Tognolini AR, Liu X, Pandey S, **Roberts JA**, Wallis SC, **Jackson D**, **Eley VA**. Dosing optimisation of intravenous lidocaine in patients with class 1-3 obesity by population pharmacokinetic analysis. *Anaesthesia*. 2025 May;80(5):511-521. doi: 10.1111/anae.16531.

Roberts DM, Liu X, Parker SL, Burke A, Peek J, Carland JE, Murnion B, Seah V, Wallis SC, Sumi CD, Pandey S, Buscher H, Byrne A, Sandaradura I, Bowen D, **Holz S**, **Stewart AG**, **Hajkowicz KM**, **Roberts JA**. Population Pharmacokinetic Modelling of Remdesivir and Its Metabolite GS-441524 in Hospitalised Patients with COVID-19. *Clin Pharmacokinet*. 2025 May;64(5):743-756. doi: 10.1007/s40262-025-01496-2.

Kumta N, Heffernan AJ, Liu X, Parker SL, Cotta MO, Wallis SC, **Livermore A**, **Starr T**, Wai WT, Joynt GM, **Lipman J**, **Roberts JA**. Ceftriaxone population pharmacokinetics in plasma and cerebrospinal fluid of neurocritical care patients. *Int J Antimicrob Agents*. 2025 May;65(5):107461. doi: 10.1016/j.ijantimicag.2025.107461.

Giuliano S, Angelini J, Campanile F, Conti P, Flammini S, Pagotto A, Sbrana F, Martini L, D'Elia D, Abdul-Aziz MH, **Cotta MO**, **Roberts JA**, Bonomo RA, Tascini C. Evaluation of ampicillin plus ceftobiprole combination therapy in treating *Enterococcus faecalis* infective endocarditis and bloodstream infection. *Sci Rep*. 2025 Jan 28;15(1):3519. doi: 10.1038/s41598-025-87512-8.

Roberts JA, Sime FB, **Lipman J**, Hernández-Mitre MP, Baptista JP, Brüggemann RJ, Darvall J, De Waele JJ, Dimopoulos G, Lefrant JY, Mat Nor MB, Rello J, Seoane L, Slavin MA, Valkonen M, Venditti M, Ceccarelli G, Wong WT, Zeitlinger M, Roger C. Are contemporary antifungal doses sufficient for critically ill patients? Outcomes from an international, multicenter pharmacokinetics study for Screening Antifungal Exposure in Intensive Care Units-the SAFE-ICU study. *Intensive Care Med*. 2025 Feb;51(2):302-317. doi: 10.1007/s00134-025-07793-5.

Gurunathan U, Medcalf RL, Chiang L, Liu Z, Liu X, Keragala CB, Hernandez-Mitre MP, Brady P, Wallis SC, **Roberts JA**, Mullany D, Nandurkar H, **Eley V**, Parker SL. A pharmacokinetic/pharmacodynamic analysis of intravenous tranexamic acid in adult patients undergoing elective total hip arthroplasty (ORACLE). *Br J Anaesth*. 2025 Jan 22:S0007-0912(24)00721-9. doi: 10.1016/j.bja.2024.12.004.

Abbott IJ, Anderson CRB, van Gorp E, Wallis SC, **Roberts JA**, Meletiadiis J, Peleg AY. Oral ciprofloxacin biofilm activity in a catheter-associated urinary tract infection model. *J Antimicrob Chemother*. 2025 Feb 3;80(2):413-426. doi: 10.1093/jac/dkac424.

Kumta N, Heffernan AJ, Cotta MO, Liu X, Parker S, Wallis S, **Livermore A**, **Starr T**, Wong WT, Joynt GM, **Lipman J**, **Roberts JA**. Population pharmacokinetics of piperacillin-tazobactam in the plasma and cerebrospinal fluid of critically ill patients. *Antimicrob Agents Chemother*. 2025 Feb 13;69(2):e0060124. doi: 10.1128/aac.00601-24.

Murray F, Yoo O, Brophy-Williams S, Rawlins M, Wallis SC, **Roberts JA**, Raby E, Salman S, Manning L. Safety, tolerability and pharmacokinetics of subcutaneous meropenem as an alternative to intravenous administration. *J Antimicrob Chemother*. 2025 Jan 3;80(1):209-215. doi: 10.1093/jac/dkac398.

Ren C, Huang F, Cheng V, Xie J, **Roberts JA**, Abdul-Aziz MH. Antibacterial Pharmacokinetics in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO): A Systematic Review of Population Pharmacokinetic Studies. *Clin Pharmacokinet*. 2025 Dec 12. doi: 10.1007/s40262-025-01596-z.

Coste A, Aubron C, Ansart S, **Roberts J**, Morio F, Grégoire M. Factors affecting voriconazole pharmacokinetic variability in critically ill patients: a systematic review. *Crit Care*. 2025 Nov 25;29(1):536. doi: 10.1186/s13054-025-05697-w.

Mohammed SA, Roberts N, Nicolás D, Unwin S, Cotta M, **Roberts JA**, Sime FB. Implementation of outpatient parenteral antimicrobial therapy program in the contemporary health care system: A narrative review of the evidence. *J Infect Public Health*. 2025 Oct;18(10):102938. doi: 10.1016/j.jiph.2025.102938.

Roger C, Koulenti D, Novy E, **Roberts J**, Dahyot-Fizelier C. Optimization of antimicrobial therapy in critically ill patients, what clinicians and searchers must know. *Anaesth Crit Care Pain Med*. 2025 Sep;44(5):101561. doi: 10.1016/j.accpm.2025.101561.

Mårtson AG, Barber KE, Crass RL, Hites M, Kloft C, Kuti JL, Nielsen EI, Pai MP, Zeitlinger M, **Roberts JA**, Tängdén T; Pharmacokinetics and Pharmacodynamics of Anti-Infectives Study Group of the European Society of Clinical Microbiology and Infectious Diseases, the International Society of Anti-Infective Pharmacology, and the Society of Infectious Diseases Pharmacists. The pharmacokinetics of antibiotics in patients with obesity: a systematic review and consensus guidelines for dose adjustments. *Lancet Infect Dis*. 2025 Sep;25(9):e504-e515. doi: 10.1016/S1473-3099(25)00155-0.

Zamri PJ, Lim SMS, Sime FB, **Roberts JA**, Abdul-Aziz MH. A Systematic Review of Pharmacokinetic Studies of Colistin and Polymyxin B in Adult Populations. *Clin Pharmacokinet*. 2025 May;64(5):655-689. doi: 10.1007/s40262-025-01488-2.

Bassetti M, Stewart A, Bartalucci C, Vena A, Giacobbe DR, **Roberts J**. Rezafungin acetate for the treatment of candidemia and invasive candidiasis: a pharmacokinetic evaluation. *Expert Opin Drug Metab Toxicol*. 2025 Jan-Feb;21(2):125-132. doi: 10.1080/17425255.2024.2424899.

Mitri EA, Fletcher LR, Paynter C, Vogrin S, James F, Ng I, Holmes NE, Ierano C, **Roberts JA**, Fernando SL, Klaic M, Trubiano JA. International Network of Antibiotic Allergy Nations (iNAAN): Protocol for a type 2 hybrid effectiveness-implementation multicentre prospective cohort and target trial emulation study evaluating penicillin allergy delabeling via direct oral challenge. *PLoS One*. 2025 Sep 5;20(9):e0330724. doi: 10.1371/journal.pone.0330724.

Journal Articles (RBWH staff or consumers in bold)

Jong T, Baird T, Barr HL, Bell S, Bigirimurame T, Brady K, Burke A, Byrnes J, Caudri D, Clark JE, Coin LJM, Goh F, Grimwood K, Hicks D, Jayawardana K, Joshi S, Lee K, Qvist T, Reid D, Rice M, **Roberts JA**, Rogers G, Shackleton C, Sly PD, Smyth AR, Stevens L, Stockwell R, Tarique A, Taylor S, Thomson R, Tiddens HAWM, Wang XF, Wason J, Wainwright C. Finding the optimal regimen for Mycobacteroides abscessus treatment (FORMaT) in people with Mycobacteroides abscessus pulmonary disease: a multicentre, randomised, multi-arm, adaptive platform trial. *BMJ Open*. 2025 Sep 21;15(9):e096188. doi: 10.1136/bmjopen-2024-096188.

Mahar RK, McGlothlin A, Dymock M, Barina L, Bonten M, Bowen A, Cheng MP, Daneman N, Goodman AL, Lee TC, Lewis RJ, Lumley T, McLean ARD, McQuilten Z, Mora J, Paterson DL, Price DJ, **Roberts J**, Snelling T, Tverring J, Webb SA, Yahav D, Davis JS, Tong SYC, Marsh JA; SNAP Global Trial Steering Committee. Statistical documentation for multi-disease, multi-domain platform trials: our experience with the Staphylococcus aureus Network Adaptive Platform trial. *Trials*. 2025 Feb 11;26(1):49. doi: 10.1186/s13063-024-08684-8.

Colmenero M, **Roberts JA**, Lipman J, Uldemolins M. Beyond the numbers: do nomograms capture the complexity of RRT dosing? Author's reply. *Intensive Care Med*. 2025 Nov;51(11):2170-2171. doi: 10.1007/s00134-025-08160-0.

Angelini J, Giuliano S, Lanini S, Ferin S, Martini L, Cossettini S, **Roberts J**, Baraldo M, Tascini C. In reply to the Letter to Editor regarding 'Renal function and its impact on the concentration of ceftazidime-avibactam: A cross-sectional study'. *Int J Antimicrob Agents*. 2025 Jun;65(6):107480. doi: 10.1016/j.ijantimicag.2025.107480.

Hernández-Mitre MP, **Roberts JA**, Roger C. Optimizing ICU antifungal therapy: overcoming pharmacokinetic limitations with combination strategies-author's reply. *Intensive Care Med*. 2025 Apr;51(4):813-814. doi: 10.1007/s00134-025-07872-7.

Tognolini A, Roberts JA, Eley VA. Optimising peri-operative intravenous lidocaine dosing regimens. *Anaesthesia*. 2025 Jul;80(7):873. doi: 10.1111/anae.16611.

Dulhunty JM, Roberts JA, Lipman J; BLING III Study Investigators. Continuous vs Intermittent β -Lactam Antibiotic Infusions for Sepsis-Reply. *JAMA*. 2025 Jan 14;333(2):174-175. doi: 10.1001/jama.2024.23275.

Roberts JA, Devaux A, Abdul-Aziz MH. Prolonged vs Intermittent Infusions of β -Lactam Antibiotics-Reply. *JAMA*. 2025 Jan 21;333(3):259. doi: 10.1001/jama.2024.23728.

Heffernan AJ, **Roberts JA**. Is it a case of higher, the worse, or are beta-lactam antibiotics the innocent bystanders? *J Crit Care*. 2025 Feb;85:154934. doi: 10.1016/j.jcrc.2024.154934.

Esneau C, Boettiger D, Leask S, Bryant NE, Niessen N, McVernon J, Marcato A, Carlson S, Browne S, Thomas R, Holmes EC, **Hajkowicz K**, Tilbrook L, Moon N, Dalton C, Bartlett NW, Davis JS. The Pandemic REspiratory Virus Epidemiological Surveillance Trial - A self-swab surveillance system for respiratory viruses nested within FluTracking. *J Infect Dis*. 2025 Dec 18;jiaf632. doi: 10.1093/infdis/jiaf632.

Hajkowicz K, Woodford J, Pillai ES, Henden A, Lowry K, Petrone ME, **Harris PNA**, Holmes EC. Metatranscriptomic Identification of Trubanaman Virus Sequences in Patient with Encephalitis, Australia. *Emerg Infect Dis*. 2025 Dec;31(12):2332-2335.

Lindsay J, Yeoh D, Teh BW, Reynolds GK, **Henden A**, McQuilten Z, Wheeler M, Hamilton A, Nelson A, **Nakagaki M**, Sandhu S, Slavin MA; Australasian Neutropenic Fever Guidelines Steering Committee. Consensus guidelines for antibacterial prophylaxis in patients with neutropenia. *Intern Med J*. 2025 Dec;55 Suppl 7:115-135. doi: 10.1111/imj.70250.

Webster R, Oyong DA, Llewellyn S, Abd-Rahman AN, Potter AJ, Mukhiya R, Sahai N, Leelasena I, Ujvary E, Mathison S, Andrew DW, Bukali L, de Labastida Rivera F, Engel J, Soon MSF, Frame T, Hamelink J, Nalubega M, Dooley NL, Loughland JR, Nguyen T, Rosenberg-Hasson Y, Maysel-Auslender S, Sigal N, Foygel K, Gower J, Peters J, Woo R, Amante F, Wells TNC, Chalon S, Moehrle JJ, McCarthy JS, Birrell GW, Edstein MD, Leipold M, Obermoser G, Maecker H, Engwerda CR, **Barber BE**, Boyle MJ. Adjunctive ruxolitinib attenuates inflammation and enhances immunity in volunteers experimentally infected with *Plasmodium falciparum*. *Sci Transl Med*. 2025 Nov 26;17(826):eaea2531. doi: 10.1126/scitranslmed.aea2531.

Lynch SA, Abd-Rahman AN, Peters JM, Heunis JM, S E Gower J, Potter AJ, Webster R, Jennings H, Mathison S, Sahai N, Amante FH, **Barber BE**. Transmissibility of a new Plasmodium falciparum 3D7 bank for use in malaria volunteer infection studies evaluating transmission blocking interventions. *Sci Rep*. 2025 Apr 16;15(1):13094. doi: 10.1038/s41598-025-97282-y.

Rathnam JTT, Grigg MJ, Dondorp AM, William T, Rajasekhar M, Rajahram G, Simpson JA, **Barber BE**, Anstey NM. Reduced Red Blood Cell Deformability in Vivax Malaria. *J Infect Dis*. 2025 Mar 17;231(3):e566-e569. doi: 10.1093/infdis/jiae490.

Gower JSE, Webster R, Westaway JAF, Tickner JA, Wang CYT, Peters JM, Andrew D, Tan AF, Webb L, Potter AJ, Woo R, Mathison S, Sahai N, Chen N, Cheng Q, Boyle MJ, Anstey NM, Grigg MJ, Woodford J, Jennings HE, Amante FH, Barber BE. Development of an experimental human blood-stage model for studying Plasmodium knowlesi. *medRxiv* 2025.09.07.25334506. doi: 10.1101/2025.09.07.25334506.

Bukali L, Engel JA, Oyong D, de Labastida Rivera F, Soon M, Andrew DW, Dooley NL, Nalubega M, Mukhiya R, Frame TCM, Hamelink J, Loughland JR, Webster R, Amante F, Wells T, Chalons S, Moehrle J, McCarthy JS, Leipold M, Obermoser G, Maecker H, **Barber BE**, Boyle MJ, Engwerda CR. Targeting type I regulatory T cells to enhance anti-parasitic T helper 1 and T follicular helper cell responses in human malaria. *medRxiv* 2025.04.09.25325416. doi: 10.1101/2025.04.09.25325416.

Journal Articles (RBWH staff or consumers in bold)

Bestgen B, Jones S, Thathy V, Kuemmerle A, Barcelo C, Haouala A, Gossen D, Marx MW, Di Resta I, Szramowska M, Webster RA, Llewellyn S, Ritacco DA, Yeo T, Leroy D, **Barber BE**, Fidock DA, Griffin P, Lickliter J, Chalon S. Safety, tolerability, pharmacokinetics, and antimalarial activity of MMV533: a phase 1a first-in-human, randomised, ascending dose and food effect study, and a phase 1b Plasmodium falciparum volunteer infection study. *Lancet Infect Dis*. 2025 May;25(5):507-518. doi: 10.1016/S1473-3099(24)00664-9.

Anstey NM, Grigg MJ, William T, Rajahram GS, Cooper DJ, **Barber BE**. Acute Kidney Injury in Non-falciparum Malaria. *Semin Nephrol*. 2025 May;45(3):151615. doi: 10.1016/j.semnephrol.2025.151615.

Eustace MB, Thean LJ, **Hovelroud RA**, **Barber BE**. An unusual case of primary pituitary abscess due to *Corynebacterium pseudodiphtheriticum*. *Eur J Clin Microbiol Infect Dis*. 2025 Feb;44(2):453-457. doi: 10.1007/s10096-024-05020-5.

Frame TCM, de Labastida Rivera F, Dooley NL, Engel JA, Na J, Wang Y, Bukali L, Ng SS, Bunn PT, Beattie L, William T, Grigg MJ, Anstey NM, McCarthy JS, **Barber BE**, Boyle MJ, Engwerda CR. Defining the roles of NKG7 expressed by CD4⁺ and CD8⁺ T cells during malaria. *bioRxiv* 2025.09.11.675499. doi: doi.org/10.1101/2025.09.11.675499.

Loughland JR, Dooley NL, Pava Z, SheelaNair A, Andrew DW, Tipping P, Bourke P, Engwerda CR, Lopez JA, Piera KA, William T, **Barber BE**, Grigg MJ, Anstey NM, Minigo G, Boyle MJ. Age is an intrinsic driver of inflammatory responses to malaria. *Nat Commun*. 2025 Sep 30;16(1):8665. doi: 10.1038/s41467-025-63638-1.

Lubis IND, Permatasari R, Siahaan L, Cahyadi RAD, Nainggolan IRA, Syafutri RD, Sinambela MN, Jauharah S, Lestari A, Theodora M, Prameswari H, Piera KA, **Barber BE**, Anstey NM, Grigg MJ. Submicroscopic Burden of Zoonotic Plasmodium knowlesi Malaria on Mursala Island and Plasmodium falciparum and Plasmodium vivax Transmission in Mainland North Sumatra, Indonesia. *Am J Trop Med Hyg*. 2025 Dec 4;114(2):292-301. doi: 10.4269/ajtmh.25-0493.

Trianty L, Amalia R, Noviyanti R, Kariodimedjo P, Fadila N, Nisa FA, Coutrier FN, Yuniarti T, Imawati I, Hidar H, Burkot TR, Piera KA, **Barber BE**, Anstey NM, Garjito TA, Grigg MJ. Severe and uncomplicated Plasmodium knowlesi malaria in North Kalimantan and Sabang, Aceh, and suspected Anopheles vectors across Kalimantan, Indonesia. *medRxiv* 2025.04.29.25326532. doi: doi.org/10.1101/2025.04.29.25326532.

Braima KA, Piera KA, Lubis IND, Noviyanti R, Rajahram GS, Kariodimedjo P, Nainggolan IRA, Permatasari R, Trianty L, Amalia R, Sakam SS, Tan AF, William T, Westaway JAF, Lee P, Daim S, Surendra H, Christy N, Letizia AG, Peatey CL, Moideen MA, **Barber BE**, Sutherland CJ, Anstey NM, Grigg MJ. Improved limit of detection for zoonotic Plasmodium knowlesi and P. cynomolgi surveillance using reverse transcription for total nucleic acid preserved samples or dried blood spots. *PLoS Negl Trop Dis*. 2025 Feb 6;19(2):e0012129. doi: 10.1371/journal.pntd.0012129.

Edler P, Rajasekhar M, Price DJ, Adam I, Awab GR, **Barber BE**, Brasil LW, Chamma-Siqueira NN, Chu CS, Cui L, Daher A, Gomes MDSM, Gonzalez-Ceron L, Grigg MJ, Karunajeewa H, Lacerda MVG, Ladeia-Andrade S, Leslie T, Ley B, Lidia K, Llanos-Cuentas A, Longley RJ, Manning L, Mekonnen DA, Monteiro WM, Moore BR, Nosten F, Pasaribu AP, Pereira DB, Poespoprodjo JR, Pukrittayakamee S, Rijal KR, Saravu K, Siqueira AM, Sutanto I, Taylor WRJ, Thanh PV, Thriemer K, Vieira JLF, White NJ, Yeshiwondim AK, Zuluaga-Idarraga LM, Guerin PJ, Simpson JA, Price RN, Commons RJ; WorldWide Antimalarial Resistance Network (WWARN) Vivax Primaquine Dosing Efficacy, Tolerability and Safety Study Group. Automated reporting of primaquine dose efficacy, tolerability and safety for Plasmodium vivax malaria using a systematic review and individual patient data meta-analysis. *Malar J*. 2025 Nov 14;24(1):400. doi: 10.1186/s12936-025-05642-w.

Westaway JAF, Diez Benavente E, Auburn S, Kucharski M, Aranciaga N, Nayak S, William T, Rajahram GS, Piera KA, Braima K, Tan AF, Alaza DA, **Barber BE**, Drakeley C, Amato R, Sutanto E, Trimarsanto H, Jelip J, Anstey NM, Bozdech Z, Field M, Grigg MJ. Genomic epidemiology of Plasmodium knowlesi reveals putative genetic drivers of adaptation in Malaysia. *PLoS Negl Trop Dis*. 2025 Mar 12;19(3):e0012885. doi: 10.1371/journal.pntd.0012885.

Kerr G, Van Huyssteen K, Webster R, **Barber BE**, Pollak NM, Hugo LE, Macdonald J. Pre-clinical evaluation of a low-resource molecular rapid Plasmodium falciparum test using infected whole blood samples. [version 1]. *VeriXiv* 2025, 2:313. doi: doi.org/10.12688/verixiv.1174.1.

Eustace MB, Braddick M, Alcorn K, Choong K, Satyaputra F, Siebert D, Smith S, Sommerville R, **McCarthy K**. Microbiological basis of central skull base osteomyelitis in Queensland, Australia, 2010–2020. *Pathology*, 2025, Volume 57, S92 - S93. doi: 10.1016/j.pathol.2024.12.380.

Book Chapters (RBWH staff or consumers in bold)

Anstey NM, **Barber BE**, William T. Knowlesi malaria. Chapter in: Up to Date, 2017 – current.

Keynote or Plenary Lectures given in 2025

Date	Title
February 2025	Roberts JA. "Real Time Drug Monitoring and Customisation". European Society of Intensive Care Medicine Intensive Care Innovation Forum. Milan, Spain. Invited Speaker.
3 March 2025	Rickard C. European Consortium for Research and Infectious Diseases (ECRAID), Cascais, Portugal. Invited Speaker.
6 March 2025	Rickard C. Catheter Related Infection Prevention. Poitiers University Hospital, Poitiers, France. Invited Speaker.
10 March 2025	Rickard C. Incorporating randomised controlled trials into a research program. Geneva University Hospital, Geneva, Switzerland. Invited Speaker.
11 March 2025	Rickard C. Catheter Related Infection Prevention. Geneva University Hospital, Geneva, Switzerland. Invited Speaker.
26 – 29 April 2025	Rickard C. What's new in PIVC research: Clinically indicated removal. Infusion Nursing Society 2025, Las Vegas, USA. Invited Speaker.
May 2025	Roberts JA. "PK/PD of Antimicrobials". New Zealand Hospital Pharmacists Association Medicines Information/Clinical Pharmacy (MICP) symposium, Auckland, NZ. Invited Speaker.
14 June 2025	Rickard C. Removal of Peripheral IV Catheters: What should we do in 2025? IV Therapy Academic Conference, Chinese Nursing Association, Beijing, China (Virtual). Keynote.
June 2025	Roberts JA. "Stability, combinations and subcutaneous infusion of antibiotics The OPAT strategies", Infezioni Difficili nel Paziente Critico (IDiPaC6), Udine, Italy. Invited Speaker.
June 2025	Roberts JA. "Beta-lactams continuous infusion vs intermittent infusion", Infezioni Difficili nel Paziente Critico (IDiPaC6), Udine, Italy. Invited Speaker.
July 2025	Roberts JA. "Precision dosing: optimising antibiotic therapy in and out of the ICU". 8 th World Bronchiectasis Conference, Brisbane, Australia. Invited Speaker.
July 2025	Roberts JA. 2025 Population Pharmacokinetics: From Fundamentals to Clinical Practice. The University of Queensland, Brisbane. Co-Convenor.
August 2025	Roberts JA. "The Next Frontier in Antibiotic Dosing: True Personalisation". Asia Pacific Intensive Care Symposium, Singapore. Plenary.
August 2025	Roberts JA. "Continuous versus extended infusion of beta-lactams". Asia Pacific Intensive Care Symposium, Singapore. Invited Speaker.
August 2025	Roberts JA. "Practicing Precisely: Optimising Antibiotics". Asia Pacific Intensive Care Symposium, Singapore. Invited Speaker.
August 2025	Roberts JA. "How can we best dose immunoglobulin? Applying PK/PD studies to immunoglobulin research". Centre of Research Excellence OPTIMAL Open Meeting, Melbourne. Invited Speaker.
12 September 2025	Rickard C. Prevention of PIVC complications and infections. Jonkoping Hospital / University of Jonkoping, Jonkoping, Sweden. Invited Speaker.
17 September 2025	Rickard C. Infection risk of peripheral intravenous catheters – Meta synthesis of 18 prospective studies with 14,606 catheters. 8 th International Conference on Prevention and Control (ICPIC), Geneva, Switzerland. Plenary Speaker.
September 2025	Roberts JA. "Antimicrobial dosing and TDM in critical illness" INTREPID Webinar, Australasian Society of Infectious Diseases (ASID), Virtual. Invited Speaker
September 2025	Roberts JA. "Antimicrobial Use in Renal Failure and MIC Targets" Ukrainian Scientific and Practical Conference: Cooperation and Innovation in the Medical Industry. Kyiv, Ukraine (Virtual). Invited Speaker.

September 2025	Roberts JA. "Prolonged infusion of beta-lactam antibiotics: current practice and future research" 9th South Taihu Lake Clinical Pharmacy Conference, Huzhou, China. Keynote.
September 2025	Roberts JA. "What is the future of therapeutic drug monitoring research" 9th South Taihu Lake Clinical Pharmacy Conference, Huzhou, China. Plenary.
September 2025	Roberts JA. "BLING 3" United Kingdom Critical Care Research Forum, Manchester, UK (Virtual). Invited Speaker.
3 November 2025	Rickard C. Developing a Funded Research Program. Edith Cowan University, Perth, Australia. Invited Speaker and Mentoring.
16 – 19 November 2025	Havers S. HREC yourself before you wreck yourself. Overcoming the barriers of ethics & governance so you can do more research in your clinical role. 2025 ACIPC International Conference, Hobart, Australia.
16 – 19 November 2025	Havers S. Infection prevention and control priorities for PIVC care – thinking past the policies. 2025 ACIPC International Conference, Hobart, Australia.
16 – 19 November 2025	Rickard C. The IVCare Adaptive Platform Trial – Levelling Up Our Evidence for Practice. 2025 ACIPC International Conference, Hobart, Australia. Invited Speaker.
16 – 19 November 2025	Rickard C. AVATAR AVAS ACIPC Conference Workshop. 2025 ACIPC International Conference, Hobart, Australia. Workshop Convenor.
16 – 19 November 2025	Schults J. Living guidelines in infection prevention and control. 2025 ACIPC International Conference, Hobart, Australia.
18 November 2025	McCarthy K. Measles in Healthcare. 2025 ACIPC International Conference, Hobart, Australia.
31 November 2025	Rickard C. International Aseptic Non Touch Technique (ANTT) Conference, London, UK (Virtual). Keynote.